These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Delavirdine/protease inhibitor interactions.
    Author: Gilden D.
    Journal: GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839.
    Abstract:
    On September 27, 1996, the Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee meets to consider licensing the non-nucleoside reverse transcriptase inhibitor (NNRTI), delavirdine (Rescriptor). How both delavirdine and nevirapine, another NNRTI, affect the body's metabolism of protease inhibitors is an issue that remains unresolved. Pharmacia & Upjohn released preliminary results of combining delavirdine with the three marketed protease inhibitors: saquinavir, ritonavir, and indinavir. Tests show delavirdine raised saquinavir levels sixfold, had no effect on ritonavir, and doubled the effective dose of indinavir.
    [Abstract] [Full Text] [Related] [New Search]